Biallelic mutation of HSD17B4 induces middle age-onset spinocerebellar ataxia

被引:8
|
作者
Matsuda, Yukiko [1 ,2 ]
Morino, Hiroyuki [1 ]
Miyamoto, Ryosuke [3 ]
Kurashige, Takashi [4 ,5 ]
Kume, Kodai [1 ]
Mizuno, Noriyoshi [6 ]
Kanaya, Yuhei [1 ]
Tada, Yui [1 ]
Ohsawa, Ryosuke [1 ]
Yokota, Kazunori [7 ]
Shimozawa, Nobuyuki [8 ]
Maruyama, Hirofumi [9 ]
Kawakami, Hideshi [1 ]
机构
[1] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Epidemiol, Hiroshima, Japan
[2] Japan Soc Promot Sci, Tokyo, Japan
[3] Tokushima Univ, Inst Biomed Sci, Dept Clin Neurosci, Tokushima, Japan
[4] Natl Hosp Org Kure Med Ctr, Dept Neurol, Kure, Japan
[5] Chugoku Canc Ctr, Kure, Japan
[6] Hiroshima Univ, Grad Sch Biomed & Sci, Dept Periodontal Med, Hiroshima, Japan
[7] Hiroshima Univ Hosp, Dept Plast Surg, Hiroshima, Japan
[8] Gifu Univ, Life Sci Res Ctr, Div Genom Res, Gifu, Japan
[9] Hiroshima Univ, Dept Clin Neurosci & Therapeut, Hiroshima, Japan
关键词
BIFUNCTIONAL PROTEIN-DEFICIENCY; SPECTRUM;
D O I
10.1212/NXG.0000000000000396
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Objective To determine the genetic underpinnings of slowly progressive spinocerebellar ataxia, autosomal recessive (SCAR), we performed exome analysis and examined the relationship between clinical severity and functional change induced by the mutation. Methods Homozygosity fingerprinting and exome sequencing were performed to identify causative mutations in 2 consanguineous families. We assessed the expression of D-bifunctional protein (DBP) and the amount of dimerized DBP in fibroblasts by immunoblot and quantitative reverse transcription PCR. The pathogenicity of the mutation was evaluated using the Combined Annotation-Dependent Depletion (CADD) scores; these results were compared with the scores of previously reported mutations. Results We identified a homozygous mutation as causative of middle age-onset SCAR: p.Ala175Thr, which is located in HSD17B4 that encodes peroxisomal DBP. The patients developed cerebellar ataxia, and the subsequent progression was slow. The symptoms presented were milder than those in previously reported cases. The messenger RNA expression levels were normal, but protein levels were diminished. Dimerization of DBP was also reduced. The CADD score of the identified mutation was lower than those of previously reported mutations. Conclusions This is the report of middle age-onset DBP deficiency. Residual functional DBP caused relatively mild symptoms in the affected patients, i.e., slowly progressive ataxia and hearing loss. This study broadens the scope of DBP deficiency phenotypes and indicates that CADD scores may be used to estimate the severity of DBP deficiencies.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] DNA methylation of HSD17B4 is involved in drug sensitivity of breast cancer through a metabolic shift
    Hattori, Naoko
    Arai, Nobuaki
    Yamashita, Satoshi
    Mukai, Hirofumi
    Ushijima, Toshikazu
    CANCER SCIENCE, 2021, 112 : 373 - 373
  • [22] 家兔HSD17B4基因与繁殖性能的关联性分析
    沈峻宇
    杨嵩
    陈定超
    冉强
    四川畜牧兽医, 2015, 42 (04) : 34 - 37
  • [23] An Artemisinin Derivative ART1 Induces Ferroptosis by Targeting the HSD17B4 Protein Essential for Lipid Metabolism and Directly Inducing Lipid Peroxidation
    Xie, Jingjing
    Zhu, Guangya
    Gao, Ming
    Xi, Jie
    Chen, Ge
    Ma, Xinxin
    Yan, Yu
    Wang, Zhiyuan
    Xu, Ze-Jun
    Chen, Hui-Jun
    Hao, Hong-Dong
    Zhang, Yaoyang
    Yao, Zhu-Jun
    Zhu, Jidong
    CCS CHEMISTRY, 2022, 4 (01): : 304 - 317
  • [24] Repeat length in spinocerebellar ataxia type 4 (SCA4) predicts age at onset and disease severity
    Dalski, Andreas
    Pauly, Martje G.
    Hanssen, Henrike
    Hagenah, Johann
    Hellenbroich, Yorck
    Schmidt, Christian
    Strohschehn, Jassemien
    Spielmann, Malte
    Zuehlke, Christine
    Brueggemann, Norbert
    JOURNAL OF NEUROLOGY, 2024, : 6289 - 6300
  • [25] PDGFRA, HSD17B4 and HMGB2 are potential therapeutic targets in polycystic ovarian syndrome and breast cancer
    Xu, Huiyu
    Han, Yong
    Lou, Jiaying
    Zhang, Hongxian
    Zhao, Yue
    Gyorffy, Balazs
    Li, Rong
    ONCOTARGET, 2017, 8 (41) : 69520 - 69526
  • [26] A homozygous missense variant in HSD17B4 identified in a consanguineous Chinese Han family with type II Perrault syndrome
    Chen, Kui
    Yang, Ke
    Luo, Su-Shan
    Chen, Chen
    Wang, Ying
    Wang, Yi-Xuan
    Li, Da-Ke
    Yang, Yu-Jie
    Tang, Yi-Lin
    Liu, Feng-Tao
    Wang, Jian
    Wu, Jian-Jun
    Sun, Yi-Min
    BMC MEDICAL GENETICS, 2017, 18
  • [27] HSD17B4 methylation enhances glucose dependence of BT-474 breast cancer cells and increases lapatinib sensitivity
    Nobuaki Arai
    Naoko Hattori
    Satoshi Yamashita
    Yu-Yu Liu
    Takahiro Ebata
    Chihiro Takeuchi
    Hideyuki Takeshima
    Satoshi Fujii
    Haruhiko Kondo
    Hirofumi Mukai
    Toshikazu Ushijima
    Breast Cancer Research and Treatment, 2023, 201 : 317 - 328
  • [28] Developing antineoplastic agents that target peroxisomal enzymes: cytisine-linked isoflavonoids as inhibitors of hydroxysteroid 17-beta-dehydrogenase-4 (HSD17B4)
    Frasinyuk, Mykhaylo S.
    Zhang, Wen
    Wyrebek, Przemyslaw
    Yu, Tianxin
    Xu, Xuehe
    Sviripa, Vitaliy M.
    Bondarenko, Svitlana P.
    Xie, Yanqi
    Ngo, Huy X.
    Morris, Andrew J.
    Mohler, James L.
    Fiandalo, Michael V.
    Watt, David S.
    Liu, Chunming
    ORGANIC & BIOMOLECULAR CHEMISTRY, 2017, 15 (36) : 7623 - 7629
  • [29] Gamma-tocotrienol Inhibits Proliferation and Growth of HSD17B4 Overexpressing HepG2 Liver Cancer Cells
    Wang, Xiaoming
    Liang, Xijia
    Zhang, Nan
    Wang, Yaqi
    Hu, Meng
    Shi, Yun
    Yao, Min
    Hou, Lianguo
    Jiang, Lingling
    CURRENT CANCER DRUG TARGETS, 2025, 25 (02) : 170 - 182
  • [30] HSD17B4 methylation enhances glucose dependence of BT-474 breast cancer cells and increases lapatinib sensitivity
    Arai, Nobuaki
    Hattori, Naoko
    Yamashita, Satoshi
    Liu, Yu-Yu
    Ebata, Takahiro
    Takeuchi, Chihiro
    Takeshima, Hideyuki
    Fujii, Satoshi
    Kondo, Haruhiko
    Mukai, Hirofumi
    Ushijima, Toshikazu
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 201 (02) : 317 - 328